Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation?

Abstract

Get full access to this article

View all access options for this article.

References

Yeo D, Hossain I, Lim ST, et al. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: an observational study. J Oncol Pharm Pract. 2018 Jan 1:1078155218763039. doi: 10.1177/1078155218763039. [Epub ahead of print].

Terrault

Bzowej

Chang

et al.

American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261–283.

Wang

Klenerman

Semmo

. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol 2017; 2: 123–134.

Bai

Chu

et al.

Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine 2012; 30: 4034–4039.

Paul

Dickstein

Saxena

et al.

Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology 2017; 66: 379–388.

Jeon JW, Kim SM, Cho H, et al. Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation. Transplantation. 2018 Apr 5. doi: 10.1097/TP.0000000000002173. [Epub ahead of print].

et al.

High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009; 48: 203–208.